- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00296829
Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly
All marketed influenza vaccines are injected by the intramuscular route. This study will test whether an influenza vaccine is effective when injected by other route than into the muscle. In order to prove this, the amount of antibodies in the blood will be measured before and after vaccination. In addition, the safety of both influenza vaccines will be tested by evaluating all serious reactions occurring after vaccination. The vaccine injected in this study is similar to the sponsor's marketed intramuscular influenza vaccine (Vaxigrip).
Primary Objective:
To demonstrate and compare the immune response of two dosages of influenza vaccine administered by an alternate route to the intramuscular administration of the vaccine.
Secondary Objectives:
- To compare the immune response 21 days after vaccination between each investigational group versus intramuscular group for each influenza strain.
- To describe the safety profile after the vaccination in each study group
- To describe the compliance of the two dosages of the vaccine administered by the alternate route with the European Medicine Agency.
Observational Objectives:
- To describe the safety profile during the 21-day period following an intramuscular revaccination in each group and the possibility of any reaction at the first injection site.
- To describe the pain at the injection site with a Visual Analog Scale and the acceptability of the injection using a questionnaire in each group.
- To describe the leakage appearing at the injection site immediately after the alternate route injection and to explore the relationship with immunogenicity.
- To evaluate the cellular mediated immune response in a subset of subjects.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Adelaide, Australia, 5000
-
Carina Heights, Australia, QLD 4152
-
Inala, Australia, QLD 4077
-
Kippa-Ring, Australia, QLD 4021
-
Victoria, Australia, 3079
-
Victoria, Australia, 3128
-
Victoria, Australia, 3144
-
Westmead, Australia, NSW 2145
-
-
-
-
-
Auckland, New Zealand
-
Dunedin, New Zealand
-
Hamilton, New Zealand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 60 to 85 years on the day of inclusion
- Informed consent form signed
- Able to attend all scheduled visits and to comply with all trial procedures.
Exclusion Criteria:
- Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances
- Febrile illness (oral temperature >= 37.5°C equivalent rectal temperature >= 38.0°C) on the day of inclusion
- Any vaccination or participation in another clinical trial in the four weeks preceding the first trial vaccination
- Planned participation in another clinical trial during the present trial period
- Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months, or long-term systemic corticosteroids therapy
- Chronic illness at a stage that could interfere with trial conduct or completion
- Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures
- Blood or blood-derived products received in the past three months
- Vaccination planned in the four weeks following the first trial vaccination
- Previous vaccination against influenza (in the previous six months) with the trial vaccine or another vaccine
- Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination
- Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GID16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on Inactivated, split-virion influenza vaccine
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae InfectionsBelgium, Germany, Switzerland
-
Butantan InstituteFundação ButantanRecruiting
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Swine-origin A/H1N1 InfluenzaFinland
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Myxovirus Infection | Orthomyxovirus InfectionsFrance
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Orthomyxoviridae InfectionsSwitzerland, United Kingdom
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Jiangsu Province Centers for Disease Control and...Jiangsu Jindike Biotechnology Co., Ltd.Completed
-
Hualan Biological Bacterin Co. Ltd.Completed
-
Sinovac Biotech Co., LtdCompletedSeasonal InfluenzaChina
-
Sanofi Pasteur, a Sanofi CompanyCompletedOrthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus InfectionBelgium